following a resubmission assessed under the end of life and orphan equivalent medicine process:
fruquintinib (Fruzaqla®) is accepted for use within NHSScotland.
Indication under review: treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with available therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, with or without an anti-VEGF therapy, and if RAS wildtype and medically appropriate, an anti-EGFR therapy.
Fruquintinib, compared with placebo, significantly improved overall survival in adults with mCRC who had been previously treated with available therapies.
This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
Medicine details
- Medicine name:
- fruquintinib (Fruzaqla)
- SMC ID:
- SMC2858
- Indication:
For the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with available therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, with or without an anti-VEGF therapy, and, if RAS wildtype and medically appropriate, an anti-EGFR therapy
- Pharmaceutical company
- Takeda UK Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Resubmission
- Status
- Accepted
- Date advice published
- 13 October 2025